Skip to main content
. Author manuscript; available in PMC: 2019 Nov 14.
Published in final edited form as: Curr Treat Options Oncol. 2017 Mar;18(3):18. doi: 10.1007/s11864-017-0444-6

Table 1.

Summary of the METEOR trial results with subgroup analyses

Subgroups (no. of pts) (cabozantinib/everolimus) Overall survival: median HR (95%CI) Progression-free survival: median HR (95%CI)
Cabozantinib (330) 21.4 months (18.4–NR) 7.4 months (5.6–9.1)
Everolimus (328) 16.5 months(14.7–18.8) 3.8 months (3.7–5.1)
HR = 0·66 [0·53–0·83] HR = 0·58 [0·45–0·75]
MSKCC risk groups:
 Favorable (150/150) 0.66 (0.46–0.96) 0.51 (0.38–0.69)
 Intermediate (139/135) 0.67 (0.48–0.94) 0.47 (0.35–0.65)
 Poor (41/43) 0.65 (0.39–1.07) 0.70 (0.42–1.16)
IMDC risk groups:
 Favorable (66/62) 0.70 (0.34–1.41) 0.47 (0.30–0.76)
 Intermediate (210/214) 0.65 (0.49–0.85) 0.48 (0.37–0.62)
 Poor (54/52) 0.74 (0.48–1.15) 0.67 (0.48–1.04)
Prior nephrectomy:
 No (47/49) 0.75(0.44–1.27) 0.51(0.30–0.86)
 Yes(283/279) 0.66(0.52–0.84) 0.51(0.41–0.64)
Bone mets
 No (253/263) 0.71(0.55–0.91) 0.57(045–0.71)
 Yes (77/65) 0.54(0.34–0.84) 0.33(0.21–0.51)
Number of previous VEGFR TKI:
 1 (235/229) 0.65(0.50–0.85) 0.52(0.41–0.66)
 2 or more (95/99) 0.73(0.48–1.10) 0.51(0.35–0.74)
Duration of first VEGFR:
 6 months or less (88/102) 0.69(0.47–1.01) 0.62(0.44–0.89)
 >6 months (242/224) 0.69(0.52–0.90) 0.48(0.38–0.62)